Inloggen

Login
 
Wachtwoord vergeten?

Esperite: een valse shuffle om snel te vergeten

Volgen
 
Klik hier om dit forumtopic te volgen en automatisch op de hoogte gehouden te worden bij nieuwe berichten.
148 Posts
Pagina: 1 2 3 4 5 6 ... 8 »» | Laatste | Omlaag ↓
  1. Bart- 13 maart 2015 12:27
    Het is zeker een shuffle. Dit heeft niks te maken met het bedrijf. Dit waren puur en alleen goudzoekers.

    Bottomline is dat dit bedrijf best potentie heeft, dat het een mooi bedrijf is en dat er toekomst in zou kunnen zitten.

    Maar dan moet je niet mee doen met deze hype. Dan moet je eerst rustig afwachten tot iedereen eruit is en het bedrijf weer wordt gewaardeerd op zijn fundamenten.

    Teksten als:

    "Stijging richting de cijfers zal wel betekenen dat het goede cijfers zijn!!"

    "4 miljoen aandelen verhandeld, dus zal er wel een overname komen"

    "Aandelen zijn bijna allemaal in vaste handen nu, ze zijn bijna op, kom maar op met dat bod"

    "Heel veel gekocht boven de 3.50 DUS de koers gaat daar weer heen" <-- erg grappig...

    Dit heeft gewoon niks met het bedrijf te maken.
    Laat de rust wederkeren, even de cijfers afwachten en dan vooral Q1 2015. Daarna zien we wel weer verder. Staat wel op mijn watchlist.

    Bart
  2. forum rang 10 DeZwarteRidder 16 maart 2015 11:39
    Een flut-bericht, maar een kinderhand is gauw gevuld......
    ++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
    Esperite tekent overeenkomst met Premaitha

    Gepubliceerd op 16 mrt 2015 om 07:41 |

    Esperite 11:19
    3,27 0,00 (+15,34%)

    ZUTPHEN (AFN) - Esperite heeft een overeenkomst getekend met het Britse Premaitha Health voor het gebruik van zijn technologie voor het vaststellen van het risico van onder meer het syndroom van Down bij foetussen. Dat maakte Esperite maandag bekend.

    Door de overeenkomst krijgt Esperite-dochter Genoma het recht voor het gebruik van de NIPT-technologie van Premaitha voor het vaststellen van afwijkingen. Met die testen kan worden ingeschat hoe groot het risico is op Down en de syndromen van Edwards en Patau. Er werden geen financiële details over de overeenkomst gemeld.
  3. forum rang 10 DeZwarteRidder 28 augustus 2015 11:51
    tophound 28 aug 2015 om 11:46:
    0
    I strongly believe that the outcome of the Cx601 European trial is just the first step towards truly transformational and exciting years to come for the company. As of today, TiGenix still owns 100% of worldwide rights to Cx601, and the biotech is now in a very favorable position to conclude high-value partnering or buy-out deals. Updating my previous value estimate to take into account the clear positive outcome of the trial (including the excellent safety profile of the therapy) and based on Cx601's value alone, I estimate TiGenix's fair value to be over $400 million - this represents a 150% upside at time of writing, illustrating why I believe TiGenix to be one of the most "deeply undervalued" biotech on the market.
  4. forum rang 10 DeZwarteRidder 29 augustus 2015 10:36
    quote:

    DeZwarteRidder schreef op 28 augustus 2015 11:51:


    tophound 28 aug 2015 om 11:46:
    0
    I strongly believe that the outcome of the Cx601 European trial is just the first step towards truly transformational and exciting years to come for the company. As of today, TiGenix still owns 100% of worldwide rights to Cx601, and the biotech is now in a very favorable position to conclude high-value partnering or buy-out deals. Updating my previous value estimate to take into account the clear positive outcome of the trial (including the excellent safety profile of the therapy) and based on Cx601's value alone, I estimate TiGenix's fair value to be over $400 million - this represents a 150% upside at time of writing, illustrating why I believe TiGenix to be one of the most "deeply undervalued" biotech on the market.


    Direct na deze posting steeg de koers met ca 10%.......!!!!
  5. forum rang 10 DeZwarteRidder 29 augustus 2015 10:37

    TiGenix Achieves First Ever Success In Allogeneic Stem Cell Phase 3 Trial
    Aug. 27, 2015 11:07 AM ET

    TiGenix's pivotal Phase 3 trial in Europe met its primary endpoint in an indication targeting a potential $2 billion orphan market.
    As predicted in my previous article, owing to solid trial design and sound science, this is the first Phase 3 success in an allogeneic stem cell trial worldwide.
    Following the FDA's agreement on the company's proposed SPA, the way is now widely open for a U.S. approval as well.
    TiGenix has also expanded its pipeline of product candidates for a various range of major diseases (RA, sepsis...) by acquiring a Phase 2 stem cell treatment for acute myocardial infarction.
    Despite clear clinical successes and strong management, the company is still deeply undervalued and a short-term upside of 150% is anticipated, with a probable NASDAQ IPO in sight.

    TiGenix (OTC:TGXSF) - listed on Euronext Brussels under ticker "TIG" - is a leading European stem cell company. The small-cap biotech has already one product on the market (ChondroCelect, an autologous chondrocyte implantation or ACI) and just announced positive Phase 3 efficacy results from its allogeneic adipose-derived stem cell treatment for Crohn's disease fistulas, Cx601. The therapy met its primary endpoint, confirming its strong potential in a $2 billion orphan market. I have extensively written before on the tremendous opportunity presented by this under-the-radar, little-known pioneering biotech with great ambitions - see a full investment thesis here and my focus article on Cx601 here - detailing why I predicted that TiGenix's Phase 3 trial would likely be a success.


    seekingalpha.com/article/3471356-tige...
  6. forum rang 10 DeZwarteRidder 29 augustus 2015 11:14
    Tigenix:

    Not only does Cx601 become the first ever recorded successful allogeneic "off-the-shelf" stem cell therapy to go through a large, randomized controlled trial, but also it is first and foremost a solid product which answers an unmet therapeutic need in a highly debilitating condition and brings hope to thousands of patients across the world. A single injection of Cx601 in highly refractory Crohn's disease patients with complex perianal fistulas was able to completely cure about 50% of all patients, whereas even the more advanced medical options like biologics (or anti-TNF alpha drugs) have poor efficacy rates (about 23%) and potentially dangerous side effects. In comparison with conventional treatments, Cx601's safety profile proved to be stellar with less treatment-related adverse events observed in the Cx601 treatment arm than in the placebo arm.

    In brief, what this means is that about one out of two patients treated with Cx601 will be spared the otherwise unavoidable surgical procedure needed to close their fistulas, which is the only option available to about four out of five patients today - surgery is a risky and painful procedure to which many doctors are reluctant, due to the difficulty of achieving sustainable results and patients' satisfaction since the rate of relapse is still very high and the outcome variable (including risks of anal incontinence). Therefore, with a much better safety profile and a more reliable closure rate than any other non-surgical option, the company's treatment becomes a significant, life-changing option, which makes it very likely that the acceptance of the product will be strong within the medical community and capture a significant portion of the target population, which represents about 120,000 new patients each year in the U.S. and Europe alone (see my previous focus article for more details).
    Cx601 is now a mostly de-risked and deeply undervalued asset...

    With this in mind and according to pricing estimations - based on Remicade which is priced around $20k per year even with less-than-impressive results and a questionable safety profile - it is estimated that peak sales of Cx601 could reach over $670 million per year with reasonable market share assumptions (see Table 1 below).
148 Posts
Pagina: 1 2 3 4 5 6 ... 8 »» | Laatste |Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Esperite Meer »

Koers 0,031   Verschil +0,00 (+0,65%)
Laag 0,030   Volume 130.918
Hoog 0,032   Gem. Volume 1.443.685
29 mei 2020 17:26
label premium

Twijfels rond Esperite

Het laatste advies leest u als IEX Premium-lid

Inloggen Ontdek Premium
 
Quotedata: Amsterdam realtime by Euronext, other realtime by Cboe Europe Ltd.   US stocks: by NYSE & Cboe BZX Exchange, 15min delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by VWD Group Crypto data by Crypto Compare